OBJECTIVES: To estimate the incremental total and per-patient budget impact of adopting certolizumab pegol (CZP) for the recently indicated treatment of active psoriatic arthritis (PsA) in Greece. METHODS: A budget impact model was adapted from a third-party payer perspective (EOPYY) to delineate the financial implications of introducing CZP for the treatment of PsA alongside currently indicated biologic treatments, namely etanercept, infliximab, adalimumab, golimumab, and ustekinumab, over the next 5 years (2014–2018). The model framework considered market share scenarios with and without CZP, and directly reimbursed costs of treatment and disease management, applied to the prevalent and eligible Greek patient population. Quarterly treatment discontinuation was geared to enable tracking of patients, so that the model could apply different costs to patients at different stages of treatment. Costs pertaining to drug acquisition, administration and monitoring were included for both the induction and maintenance years of patients’ treatment and corresponded to current costing year. Resource unit costs and epidemiological data were retrieved from officially published sources. The measured outcomes were incremental costs per treated patient per year (PTPPY) and total budget impact, calculated by comparing the respective patient and total budget expenditures with and without CZP in the market share mix scenarios. RESULTS: The incremental total and PTPPY costs resulting from the addition of CZP to the original treatment mix were estimated at -€2,036,848 (-1.76%) and -€859 respectively, over a 5-year time horizon. On average, annual cost-savings of €407,370 (-1.76%) and €172 were observed for both outcomes respectively. In each model, yearly cost-savings were yielded and 2018 was the year with the highest total cost-savings for EOPYY (€512,296 [-2.2%]). Cost-savings were driven by reduced drug and administration costs. CONCLUSIONS: The inclusion of CZP for active PsA treatment was predicted to be associated with short- and long-term cost-savings in Greece.